-
Metastatic Non-Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This year, the first three weeks of September were packed with lung cancer research updates at the World Conference on Lung Cancer (WCLC) from September 7-10 in San Diego followed by the European...
IN THE SPOTLIGHT
-
Eating Healthy on the Mediterranean Diet
Read time: 3 minutes. Oncology dietitian Lori Bumbaco takes us on a culinary journey, exploring why experts consistently rank the Mediterranean diet as the number one choice for... -
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug... -
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are... -
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming... -
HER2+ NSCLC: Understanding the Latest Treatment and Advances
Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell lung cancer (NSCLC). A... -
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community... -
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutes Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving...
Metastatic Non-Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
Metastatic Non-Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This year, the first three weeks of September were packed with lung cancer research updates at the World Conference on Lung Cancer (WCLC) from September 7-10 in San Diego followed by the European Society for Medical Oncology (ESMO) conference from September 13-17 in Barcelona. We wish we could have cloned ourselves and been in both places; however, we were able to attend WCLC in person and ESMO virtually. It’s impossible to condense so much lung cancer science into a single blog, so…
Eating Healthy on the Mediterranean Diet
Eating Healthy on the Mediterranean Diet
Read time: 3 minutes. Oncology dietitian Lori Bumbaco takes us on a culinary journey, exploring why experts consistently rank the Mediterranean diet as the number one choice for healthy eating. In addition to the studied health benefits, Lori highlights the unique foods and flavors that make this diet special and provides simple, practical tips on how to incorporate them into your daily meals. In the video below, Lori offers a firsthand look at how easy and enjoyable it can be…
Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer
Oncology expert reveals the impact of biomarker testing on the outcomes of targeted therapies for cancer
Taletrectinib Extends Cancer-Free Time With Fewer Neurological Side Effects in NSCLC Patients
Taletrectinib Extends Cancer-Free Time With Fewer Neurological Side Effects in NSCLC Patients
Encorafenib Plus Binimetinib Shows ‘Prolonged Efficacy’ in Metastatic NSCLC
SOHO-01 and FURTHER: Dr. Xiuning Le Discusses IASLC Presidential Symposium Presentations
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Phase II Study of Taletrectinib Shows Clinically Meaningful Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer
Phase II Study of Taletrectinib Shows Clinically Meaningful Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer
Breakthrough Therapy BAY 2927088 Demonstrates Rapid, Substantial and Durable Efficacy in Patients with HER2-Mutant NSCLC
Breakthrough Therapy BAY 2927088 Demonstrates Rapid, Substantial and Durable Efficacy in Patients with HER2-Mutant NSCLC
Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024
Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024
WCLC: Bayer, Boehringer face off on HER2 cancers
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug Development? Part 2: How We Define Success for a Clinical Trial The United States federal government aims to regulate prescription drugs to ensure people are receiving medication that’s safe and effective. Every prescribed drug in the U.S. has gone through a rigorous testing process that can…
How We Define Success for a Clinical Trial
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. We all want a treatment for lung cancer that is completely safe and entirely effective. While researchers are working toward that goal, the reality is we aren’t there yet. Every treatment we are considering comes with potential benefits and side effects. The…
Understanding Clinical Trials: Why Are They Important for Drug Development?
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes.This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.According to the National Cancer Institute, a clinical trial is a type of research study that tests how well new medical approaches (such as screening tests, prevention…
HER2+ NSCLC: Understanding the Latest Treatment and Advances
HER2+ NSCLC: Understanding the Latest Treatment and Advances
Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell lung cancer (NSCLC). A lot is known about how to treat HER2 in breast cancer, and researchers are leveraging that knowledge to bring treatment options to people living with HER2-positive NSCLC. In the video below, Dr. Ibiayi Dagogo-Jack, assistant professor of Medicine at Harvard Medical School and thoracic oncologist at…
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for…
How Can Patients and Researchers Design Clinical Trials Together?
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist…
2024 ASCO: Highlights of Lung Cancer Research
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutesThousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 through June 4, 2024. The theme for this year’s conference, “The Art and Science of Cancer Care: From Comfort to Cure,” highlighted the importance of using both our creativity and our scientific…
Repotrectinib Approvals Expand to Include Patients with NTRK+ Solid Tumors
Repotrectinib Approvals Expand to Include Patients with NTRK+ Solid Tumors
On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK-positive solid tumors who have either had their disease recur or who don’t have alternative treatment options. This treatment is part of a growing trend of tissue-agnostic drugs—treatments that are prescribed based on the biomarkers found in the tumor rather than the organ where the cancer originated. It is available to…
Is Lung Cancer in Young Adults Hereditary?
Is Lung Cancer in Young Adults Hereditary?
Read time: 2 minutesThe question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer diagnosis is approximately 70 years old, we are now seeing young adults in their 20s and 30s getting lung cancer.We currently suspect lung cancer in young adults may be caused by environmental factors (such as air pollution or chemical exposure), their genetic make-up, or some combination of these factors.We cannot say for…
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed with advanced-stage lung cancer. Research is ongoing to help us develop effective options to treat these patients medically, but little is known about the effects of the diagnosis on their mental, social, and financial health or their family planning. To help us better understand the needs of this growing…
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation. Her involvement with the medical system from these different perspectives inspired her to write her recent book, Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical System. You can watch the full 40-minute conversation with Kathy or use the timestamps below to learn more about the topics and advice…
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutesIntegrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of…
Kicking Drug Resistance to the Curb in RET-positive Lung Cancer
Kicking Drug Resistance to the Curb in RET-positive Lung Cancer
Read time: 4 minutes Lung cancers that test positive for the RET biomarker are often treated with targeted therapy. While this type of treatment has improved the duration and quality of life for many people living with lung cancer, we know that eventually these tumor cells develop drug resistance and begin to grow again. Researchers have been trying to understand what causes this drug resistance so we can develop treatment approaches to extend the time patients can effectively be treated…
Leveraging Basic Science to Stop Drug Resistance in RET+ Lung Cancer
Leveraging Basic Science to Stop Drug Resistance in RET+ Lung Cancer
Advances in targeted therapies have allowed us to treat some types of lung cancer with mutations in specific genes (for example, EGFR, KRAS, and RET). This has given some patients with lung cancer a better quality of life and longer survival. However, even after an initial response to the targeted therapy, lung tumors will eventually grow again. Research suggests this drug resistance is likely to involve drug-tolerant persister cells, or DTPCs—cells that tolerate the drug and persist after…
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutesIt’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of you who are new to this meeting, it is the largest gathering of laboratory scientists and clinicians in the world—coming together to discuss how to take science from the bench (laboratory) to patients and communities. This year’s meeting was held in sunny San Diego and brought together more than 23,000 attendees. Below…
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her…
FDA Grants Accelerated Approval for HER2+ Cancer Treatment
FDA Grants Accelerated Approval for HER2+ Cancer Treatment
On April 5, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of fam-trastuzumab deruxtecan-nxki (Enhertu®) to treat patients with unresectable or metastatic HER2-positive solid tumors.This treatment is part of a growing trend of tissue-agnostic drugs -- treatments that are prescribed based on the biomarkers found in the tumor rather than the organ where the cancer originated. It is available to patients through the FDA’s accelerated approval process,…
Caregivers: Planning the Self-Care Journey
Caregivers: Planning the Self-Care Journey
This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase. The discussion features Michelle Bolden, founder and chief education officer for Call For Caring Inc., a nonprofit organization educating and uplifting family caregivers in Atlanta. Michelle also hosts two podcasts -- "Call For Caring on Purpose" and "The Empowerment Hour." The webinar was recorded on March 7, 2024, as a Facebook Live event. It is hosted…
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Read time: 4 minutesI just returned from the Cancer Grand Challenges Summit, held March 5–8, 2024 in London, England. Cancer Grand Challenges was launched in 2020 as a collaboration between Cancer Research UK and the National Cancer Institute in the US, whereby they provide $25 million to international, multi-institutional teams working to address some of the most perplexing issues in the cancer field. I am LUNGevity’s representative on Team CANCAN, which is working to understand and treat…